RT Journal Article
T1 O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications.
A1 Oliver, Jaime A.
A1 Gómez-Millán, Jaime
A1 Medina, Jose A.
A1 Cabeza, Laura
A1 Perazzoli, Gloria
A1 Jimenez-Luna, Cristina
A1 Doello, Kevin
A1 Ortiz, Raúl
K1 Chemoradiotherapy
K1 O6-methylguanine-DNA methyltransferase
K1 rectal adenocarcinoma
AB To analyze the clinical relevance of O6-methylguanine-DNA methyltransferase in rectal adenocarcinoma treated with chemoradiotherapy followed by surgery. Tissue samples from 29 rectal adenocarcinoma patients were obtained after chemoradiotherapy. O6-methylguanine-DNA methyltransferase promoter methylation status was established by methylation-specific polymerase chain reaction. O6-methylguanine-DNA methyltransferase protein levels were determined by immunohistochemistry. Clinicopathologic variables, including treatment regression grade, recurrence, lymph node invasion, and stage and differentiation grade of the tumor, were determined. The O6-methylguanine-DNA methyltransferase gene promoter was methylated in 81.5% of samples. Most patients (88.9%) showed low O6-methylguanine-DNA methyltransferase protein expression. O6-methylguanine-DNA methyltransferase methylation status was not correlated with any of the clinicopathological variables determined in rectal adenocarcinomas selected for chemoradiotherapy. O6-methylguanine-DNA methyltransferase methylation status is not correlated with clinicopathologic variables examined in rectal adenocarcinoma selected for chemoradiotherapy, although its role as a biomarker awaits further investigation.
YR 2019
FD 2019-06-14
LK https://hdl.handle.net/10668/26485
UL https://hdl.handle.net/10668/26485
LA en
DS RISalud
RD Apr 11, 2025